Research may pave the way for systemic targeted therapy for patients with pseudomyxoma peritonei

FHS
July 20, 2024
12:19 am

Published in Clinical Cancer Research, results of a preclinical study led by investigators of the Vall d’Hebron Institute of Oncology’s (VHIO) Stem Cells and Cancer Group, headed by Héctor G. Palmer, pave the way for systemic targeted therapy in patients with pseudomyxoma peritonei, a rare form of cancer with very few therapeutic options available.

Unpacking IRA price negotiations results; Lykos’ tough week; Genentech rethinks cancer immunology; and more

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 18, 2024

Bridging Healthcare Disparities in Limb Loss Through Data-Driven Strategies

Shawn Murphy, VP, Thought Leadership & Innovation Foundation (TLI) Limb loss and limb difference impact millions of people globally, with over 2.3 million individuals in

December 11, 2024

NIH develops AI algorithm to streamline clinical trial matching

Researchers from the National Institutes of Health (NIH) have developed an artificial intelligence (AI) algorithm to help speed up the process of matching potential volunteers

November 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.